Skip to main
PHGE

BiomX Inc. (PHGE) Stock Forecast & Price Target

BiomX Inc. (PHGE) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BiomX Inc. is making significant strides in the development of innovative phage therapies, particularly with its BX004 and BX011 product candidates targeting chronic pulmonary infections and diabetic foot osteomyelitis, respectively. The company recently received positive feedback from the FDA, which supports the advancement of BX011 into a Phase 2a study and indicates a clear regulatory pathway, enhancing the potential for market penetration and commercial success. Furthermore, BiomX's ability to broaden its valuation through additional indications and expansion beyond the U.S. market presents substantial upside opportunities for the firm's overall financial outlook.

Bears say

BiomX Inc faces significant financial challenges that contribute to a negative outlook on its stock, primarily stemming from the risk of failed or inconclusive clinical trials for its therapeutic candidates. The company's ability to secure adequate funding is also in question, which could hinder progress in drug development and may lead to dilutive capital raises. Furthermore, the lack of commercial success for its products poses a risk to achieving financial stability and growth.

BiomX Inc. (PHGE) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BiomX Inc. (PHGE) Forecast

Analysts have given BiomX Inc. (PHGE) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BiomX Inc. (PHGE) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BiomX Inc. (PHGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.